Clinical Trial Update: BCMA CAR-T for Dynamic High-risk Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a BCMA-targeted CAR-T therapy for dynamic high-risk multiple myeloma, with recruitment ongoing in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T therapy (BCMA-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING